NSE: BIOCON | BSE: 532523

Mid-range Performer

Download real time

375.80 6.45 (1.75%)

29.14% Gain from 52W Low

3.0M NSE+BSE Volume

NSE 09 Jul, 2025 12:52 PM (IST)

50,243.1

Market Cap

Market Leader

1.2

Beta 1Year

High Volatility

Biocon Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for BIOCON, BSE:532523 Biocon Ltd.

Biocon Ltd.

17 Sep 2021

375.80

1.75%

Biocon

Hold: Biocon Ltd.

Target

ICICI Securities Limited

BBL also entered into a strategic alliance with SILS with an offer of 15% stake in BBL with post money valuation of BBL ~ US$4.9 billion. The alliance gives BBL access to 100 million doses of vaccines/annum for 15 years with commercialisation rights (including Covid-19 vaccines) for global markets The strategic alliance will also develop antibodies along with a service level agreement (SLAs) for manufacturing and distribution of the vaccines and antibodies. Additionally, Biocon Biologics will establish, at its cost, a vaccine R&D; division for developing both vaccines and biologics for communicable...

Biocon Ltd. has an average target of 389.25 from 4 brokers.

Biocon Ltd.

26 Jul 2021

375.80

1.75%

Result Update:Biocon

Hold: Biocon Ltd.

Recommendation Target

Axis Direct

Biocon reported weak numbers from the last 3 quarters, as the industry is facing price erosion challenges. Furthermore, the company is trading at rich valuations therefore we recommend HOLD with TP Rs 400.

Biocon Ltd. is trading above all available SMAs

Biocon Ltd.

23 Jul 2021

375.80

1.75%

Biocon

Hold: Biocon Ltd.

Target

ICICI Securities Limited

Biocon Ltd. has an average target of 389.25 from 4 brokers.

Biocon Ltd.

04 May 2021

375.80

1.75%

BIOCON LTD

Buy: Biocon Ltd.

Target

Geojit BNP Paribas

We expect Biocon to witness long-term sustainable growth on the back of strong pipeline, new launches and increasing investments. We remain positive on the stock and reiterate our BUY rating with a revised target price of Rs. 430 based on 34x FY23E adj. EPS....

Biocon Ltd. is trading above all available SMAs

Biocon Ltd.

30 Apr 2021

375.80

1.75%

Result Update:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

We believe, Biocon Ltd is well placed to grab upcoming opportunities in the biosimilars market in the next 5 years. However, due to rich valuations, there is limited upside potential to retain. "Buy" with a TP of Rs 430.

Biocon Ltd. is trading above all available SMAs

Biocon Ltd.

29 Apr 2021

375.80

1.75%

Approvals/faster traction to lead to better future growth

Neutral: Biocon Ltd.

Target

Motilal Oswal

BIOS delivered lower-than-expected 4QFY21 result due to: a) moderation in performance of Biosimilars, and b) sluggish growth in Generics. While the business environment remains challenging on account of COVID-19, it continues to build a product pipeline of Biosimilars/Generics to create a foundation for growth over the next 4-5 years. We lower our FY22E/FY23E EPS estimate by 10%/3%, factoring in a delay in: a) approvals for Biosimilars in the US, b) award of tenders in emerging markets, c) gradual build-up of the insulin glargine business, and d)...

Number of FII/FPI investors increased from 297 to 305 in Mar 2025 qtr.

Biocon Ltd.

29 Apr 2021

375.80

1.75%

Biocon

Hold: Biocon Ltd.

Recommendation Target

ICICI Securities Limited

Q4FY21 revenues grew 16.3% YoY to | 1839 crore. Biosimilars grew 53.2% YoY to | 664 crore due to low base effect. Research services segment grew 8.4% YoY at | 659 crore. Generic sales grew 2.7% YoY to | 578 crore due to pricing pressure and stockpiling by customers in H1FY21. EBITDA margins improved 355 bps YoY to 23.7% mainly due to strong gross margins and lower R&D; cost. EBITDA grew 36.8% YoY to | 436 crore vs. I-direct estimate of | 470 crore. Adjusted PAT grew 96.6% YoY to | 243 crore. Delta vis--vis EBITDA was due to higher other income, which included | 160 crore gain...

Biocon Ltd. has an average target of 389.25 from 4 brokers.

Biocon Ltd.

02 Feb 2021

375.80

1.75%

BIOCON LTD

Buy: Biocon Ltd.

Target

Geojit BNP Paribas

the integrated drug discovery platform (IDD) with four new projects from Deerfield 550 Discovery and Development (3DC). However, revenue from Generics segment declined 450 2.7% YoY to Rs. 561cr, impacted by advance buying owing to pandemic, supply 350 disruption and delay of approval of certain key products. Margin contracted on higher R&D; expenses EBITDA stood at Rs. 427cr, decline of 11.0% YoY, with margin contracting 490bps YoY to 23.1%, mainly due to higher R&D; expenses and employee cost related to Biosimilars business. Gross R&D; spends increased 18.1% YoY to Rs. 183cr and employee cost as a...

Biocon Ltd. is trading above all available SMAs

Biocon Ltd.

25 Jan 2021

375.80

1.75%

Result Update:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

We recommend BUY' with target price of INR 435 (35x FY22E earnings).

Number of FII/FPI investors increased from 297 to 305 in Mar 2025 qtr.

Biocon Ltd.

03 Jan 2021

375.80

1.75%

Biocon

Buy: Biocon Ltd.

Sharekhan

We retain Buy recommendation on the stock of Biocon with a revised PT of Rs. 520. Biologics segment is expected to be a significant growth driver and the company is well placed to harness the opportunities emerging in global biosimilars space. Sturdy growth prospects, strong earnings visibility, healthy balance sheet position and lower debt-equity augur well for the company. The possible listing of its wholly owned subsidiary - Biocon Biologics Limited...

Biocon Ltd. is trading above all available SMAs

Is Biocon Ltd. worth buying?

721 Votes:

Buy 75.03%

Sell 16.23%

Hold 8.74%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf